Ulteriori informazioni
Recent achievements in the development of new techniques and agents for the treatment of cancer in general as well as for soft tissue sarcomas are tremendous. Molecular biology research has changed the landscape considerably and an increasing number of subtypes of soft tissue sarcomas are related to changes in cellular growth factors in the cell signaling pathways. This enables the development of targeted agents with specific activity against these factors. The presence of the KIT receptor at the surface of the gastrointestinal stroma tumor cell, and the activation constituted by mutations has led to the discovery of an extremely active specific KIT tyrosine kinase inhibitor.
In accordance with the more targeted approach in drug use, the changes in the field of radiation therapy and surgery basically focus on a better targeting of the disease, albeit not yet based on the molecular characteristics. All of these stress the importance of the multidisciplinary approach to the treatment of soft tissue sarcoma that was the focus of previous editions of this book.
Targeting Treatment of Soft Tissue Sarcomas summarizes the recent events in this field, putting the achievements in perspective. Physicians and researchers working in the field of soft tissue sarcomas must be aware of the changes in treatment, the underlying concepts, and of the changes we face in the future.
Sommario
Targeted therapy: Ready for prime time?.- Volume-based radiotherapy targeting in soft tissue sarcoma.- Preoperative therapy for soft tissue sarcoma.- TNF-based isolated limb perfusion: A decade of experience with antivascular therapy in the management of locally advanced extremity soft tissue sarcomas.- Pitfalls in pathology of soft tissue sarcomas.- Molecular biology and cytogenetics of soft tissue sarcomas: Relevance for targeted therapies.- KIT and PDGF as targets.- Targeting mutant kinases in Gastrointestinal Stromal Tumors: A paradigm for molecular therapy of other sarcomas.- Targeting other abnormal signaling pathways in sarcoma: EGFR in synovial sarcomas, PPAR-? in liposarcomas.- Angiogenesis: a potential target for therapy of soft tissue sarcomas.
Riassunto
Recent achievements in the development of new techniques and agents for the treatment of cancer in general as well as for soft tissue sarcomas are tremendous. Molecular biology research has changed the landscape considerably and an increasing number of subtypes of soft tissue sarcomas are related to changes in cellular growth factors in the cell signaling pathways. This enables the development of targeted agents with specific activity against these factors. The presence of the KIT receptor at the surface of the gastrointestinal stroma tumor cell, and the activation constituted by mutations has led to the discovery of an extremely active specific KIT tyrosine kinase inhibitor.
In accordance with the more targeted approach in drug use, the changes in the field of radiation therapy and surgery basically focus on a better targeting of the disease, albeit not yet based on the molecular characteristics. All of these stress the importance of the multidisciplinary approach to the treatment of soft tissue sarcoma that was the focus of previous editions of this book.
Targeting Treatment of Soft Tissue Sarcomas summarizes the recent events in this field, putting the achievements in perspective. Physicians and researchers working in the field of soft tissue sarcomas must be aware of the changes in treatment, the underlying concepts, and of the changes we face in the future.
Testo aggiuntivo
"The management of soft tissue sarcomas remains a difficult challenge. However, significant advances have occurred in our understanding of the important signaling molecules in these diseases. Experts in the field discuss the critical therapeutic targets and relevant treatment strategies for these malignancies."
(Steven T. Rosen, M.D., Series Editor)
Relazione
"The management of soft tissue sarcomas remains a difficult challenge. However, significant advances have occurred in our understanding of the important signaling molecules in these diseases. Experts in the field discuss the critical therapeutic targets and relevant treatment strategies for these malignancies."
(Steven T. Rosen, M.D., Series Editor)
